NeurAxis, Inc. ( (NRXS) ) has released its Q2 earnings. Here is a breakdown of the information NeurAxis, Inc. presented to its investors.
TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
NeurAxis, Inc. is a medical technology company specializing in neuromodulation therapies for chronic conditions in both children and adults, with a focus on advancing its proprietary IB-Stim™ therapy.
In its second quarter of 2025, NeurAxis reported a significant 46% increase in revenues, reaching $894,000 compared to the same period last year. The company also noted a decrease in operating expenses by 10% and an improvement in operating loss by 22% year-over-year.
Key financial metrics highlighted include a substantial rise in unit sales by 58%, driven by increased insurance reimbursements and a financial assistance program. Despite a decline in gross margin to 83.6% due to higher discounting, the company secured $5 million through an equity-only financing round. NeurAxis also achieved several operational milestones, including FDA clearances and expanded insurance coverage.
Looking ahead, NeurAxis management remains optimistic about the company’s growth trajectory, emphasizing the potential for substantial revenue growth and improved margins as they expand insurance coverage and commercialize IB-Stim on a larger scale. The company aims to achieve breakeven by 2026, supported by strategic positioning and strong revenue momentum.